Unconventional Anticancer Metallodrugs and Strategies to Improve their Pharmacological ProfileMaria Contel For the past 40 years, metal-based drugs have been widely used for the treatment of cancer. Cisplatin and follow-up drugs carboplatin (ParaplatinTM) and oxaliplatin (EloxatinTM) have been the gold standard for metallodrugs in clinical settings as antineoplastic agents. While effective, these drugs (either alone or in combination therapy) have faced a number of clinical challenges resulting from their limited spectrum of activity, high toxicity leading to significant side effects, resistance, poor water solubility, low bioavailability and short circulating time. In the past 10 years, various unconventional non-platinum metal-based agents have emerged as a potential alternative for cancer treatment. These compounds are highly effective and selective in cancers resistant to cisplatin and other chemotherapeutic agents. Research in this area has recently exploded with a relevant number of patents and clinical trials, in addition to reports in scientific journals. Furthermore, in parallel to the synthesis of coordination and organometallic compounds comprising many different metals and unconventional platinum-based derivatives, researchers are focused on optimizing mechanistic and pharmacological features of promising drug candidates. This Special Issue aims to highlight the latest advances in anticancer metallodrugs with a focus on unconventional anticancer agents, as well as novel activation, targeting and delivery strategies aimed at improving their pharmacological profile. |
Common terms and phrases
Absorption acid activity addition agents analysis anticancer apoptosis applications Au(III binding Biochem biological breast cancer cells cell lines cellular changes chelators Chem Chemistry chromatography cisplatin clinical compared complexes compounds concentration conjugates containing coordination copper corresponding CrossRef CrossRef][PubMed cytotoxicity delivery demonstrated derivatives determined disease drug effects enhanced expression Figure fluorescence formation function gold growth higher human imaging increase incubation indicating induced inhibition Inorg interaction iron leading levels ligand lipophilicity mechanism metal method molecules nanoparticles observed obtained oxidation pathway phase platinum platinum(IV potential presence previously properties protein PubMed reaction reactivity reduced release reported role ruthenium sample selective showed shown signal solution species spectra structure studies Synthesis Table temperature therapy toxicity Trans treatment tumor values vitro vivo yield zinc